CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
3.4175
2.4%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.1850
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Beyondspring Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 3.3375
Open* 3.4775
1-Year Change* 219.3%
Day's Range* 3.3675 - 3.5575
52 wk Range 0.65-3.45
Average Volume (10 days) 34.41K
Average Volume (3 months) 964.44K
Market Cap 35.03M
P/E Ratio -100.00K
Shares Outstanding 38.92M
Revenue 1.35M
EPS -0.85
Dividend (Yield %) N/A
Beta -0.14
Next Earnings Date Feb 28, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 28, 2024 3.4175 -0.0700 -2.01% 3.4875 3.5875 3.2575
Mar 27, 2024 3.3375 -0.2700 -7.48% 3.6075 3.6175 3.3375
Mar 26, 2024 3.4475 0.1200 3.61% 3.3275 3.7175 3.1875
Mar 25, 2024 3.3175 0.3000 9.94% 3.0175 3.4575 2.8475
Mar 22, 2024 3.0475 0.3000 10.92% 2.7475 3.0775 2.7475
Mar 21, 2024 2.8675 -0.2200 -7.13% 3.0875 3.0875 2.7975
Mar 20, 2024 2.9275 -0.0400 -1.35% 2.9675 3.1275 2.7675
Mar 19, 2024 3.0175 0.0600 2.03% 2.9575 3.2675 2.7175
Mar 18, 2024 2.7775 -0.1000 -3.48% 2.8775 2.9475 2.7475
Mar 15, 2024 2.7375 -0.0800 -2.84% 2.8175 2.9575 2.7375
Mar 14, 2024 2.7575 -0.1400 -4.83% 2.8975 2.9675 2.7575
Mar 13, 2024 2.9575 0.1000 3.50% 2.8575 2.9675 2.6875
Mar 12, 2024 2.9375 -0.0200 -0.68% 2.9575 3.0075 2.6675
Mar 11, 2024 2.9575 0.0900 3.14% 2.8675 3.0375 2.7775
Mar 8, 2024 2.8175 0.0600 2.18% 2.7575 2.8975 2.6175
Mar 7, 2024 2.7575 -0.6100 -18.11% 3.3675 3.3675 2.4375
Mar 6, 2024 3.3575 0.4800 16.68% 2.8775 3.9375 2.7375
Mar 5, 2024 2.6775 1.0200 61.54% 1.6575 3.0875 1.6575
Mar 4, 2024 1.5475 0.0500 3.34% 1.4975 1.8675 1.4175
Mar 1, 2024 1.4475 0.1700 13.31% 1.2775 1.5375 1.2775

BeyondSpring Inc. Events

Time (UTC) Country Event
Thursday, April 18, 2024

Time (UTC)

20:00

Country

US

Event

Full Year 2023 Beyondspring Inc Earnings Release
Full Year 2023 Beyondspring Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 1.351 1.351 0.18 0 0
Revenue 1.351 1.351 0.18 0 0
Total Operating Expense 38.59 66.956 64.391 40.307 57.545
Selling/General/Admin. Expenses, Total 13.008 30.703 22.598 8.965 5.927
Research & Development 25.582 36.888 41.793 31.342 51.618
Operating Income -37.239 -65.605 -64.211 -40.307 -57.545
Interest Income (Expense), Net Non-Operating -0.251 0.242 0.386 -0.026 -0.244
Gain (Loss) on Sale of Assets
Net Income Before Taxes -36.117 -64.638 -63.821 -40.333 -57.474
Net Income After Taxes -36.28 -68.208 -63.821 -40.333 -57.474
Minority Interest 3.001 4.029 2.848 2.248 2.605
Net Income Before Extra. Items -33.279 -64.179 -60.973 -38.085 -54.869
Net Income -33.279 -64.179 -60.973 -38.085 -54.869
Income Available to Common Excl. Extra. Items -33.279 -64.179 -60.973 -38.085 -54.869
Income Available to Common Incl. Extra. Items -33.279 -64.179 -60.973 -38.085 -54.869
Dilution Adjustment
Diluted Net Income -33.279 -64.179 -60.973 -38.085 -54.869
Diluted Weighted Average Shares 39.0933 39.0236 29.9843 24.6457 22.6653
Diluted EPS Excluding Extraordinary Items -0.85127 -1.64462 -2.0335 -1.5453 -2.42084
Dividends per Share - Common Stock Primary Issue
Diluted Normalized EPS -0.85127 -1.6552 -2.0335 -1.5453 -2.42084
Other, Net 1.373 0.725 0.004 0 0.315
Total Extraordinary Items 0
Unusual Expense (Income) -0.635
Dec 2022 Jun 2022 Dec 2021 Sep 2021 Jun 2021
Total revenue 1.351 0.676 0.338 0.337 0.338
Revenue 1.351 0.676 0.338 0.337 0.338
Total Operating Expense 38.59 21.484 10.83 18.686 20.317
Selling/General/Admin. Expenses, Total 13.008 7.492 5.044 10.227 8.985
Research & Development 25.582 13.992 5.786 8.459 11.332
Operating Income -37.239 -20.808 -10.492 -18.349 -19.979
Interest Income (Expense), Net Non-Operating -0.251 -0.326 0.138 0.045 0.082
Other, Net 1.373 1.259 0.608 0.749 0.003
Net Income Before Taxes -36.117 -19.875 -9.746 -17.555 -19.894
Net Income After Taxes -36.28 -20.164 -10.728 -20.143 -19.894
Minority Interest 3.001 1.675 1.215 1.773 0.586
Net Income Before Extra. Items -33.279 -18.489 -9.513 -18.37 -19.308
Net Income -33.279 -18.489 -9.513 -18.37 -19.308
Income Available to Common Excl. Extra. Items -33.279 -18.489 -9.513 -18.37 -19.308
Income Available to Common Incl. Extra. Items -33.279 -18.489 -9.513 -18.37 -19.308
Diluted Net Income -33.279 -18.489 -9.513 -18.37 -19.308
Diluted Weighted Average Shares 39.0933 39.0657 39.054 39.0249 39.0109
Diluted EPS Excluding Extraordinary Items -0.85127 -0.47328 -0.24359 -0.47073 -0.49494
Diluted Normalized EPS -0.85127 -0.47328 -0.24359 -0.47073 -0.49494
Dividends per Share - Common Stock Primary Issue 0 0
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 38.523 75.123 113.4 40.862 5.871
Cash and Short Term Investments 37.268 72.368 109.537 35.933 3.889
Cash 109.537 35.933 3.889
Prepaid Expenses 1.255 2.755 3.863 4.929 1.982
Other Current Assets, Total
Total Assets 46.222 81.648 117.038 44.555 7.063
Property/Plant/Equipment, Total - Net 7.352 3.406 2.358 2.747 0.282
Property/Plant/Equipment, Total - Gross 7.903 3.725 2.616 2.928 0.386
Accumulated Depreciation, Total -0.551 -0.319 -0.258 -0.181 -0.104
Other Long Term Assets, Total 0.347 3.119 1.28 0.946 0.91
Total Current Liabilities 7.352 15.155 13.766 10.053 16.445
Accounts Payable 1.081 1.656 2.216 2.537 9.586
Accrued Expenses 4.782 6.625 9.473 6.398 5.495
Notes Payable/Short Term Debt 0 0 0 0.029 0
Other Current Liabilities, Total 1.489 5.305 2.077 1.089 1.364
Total Liabilities 52.201 54.964 28.698 14.278 14.829
Total Long Term Debt 0 0 2.167 1.436 0
Minority Interest 2.972 -0.307 3.481 0.854 -1.616
Total Equity -5.979 26.684 88.34 30.277 -7.766
Common Stock 0.004 0.004 0.004 0.003 0.002
Additional Paid-In Capital 368.857 369.2 366.451 246.979 170.95
Retained Earnings (Accumulated Deficit) -375.276 -341.997 -277.818 -216.845 -178.76
Other Equity, Total 0.436 -0.528 -0.297 0.14 0.042
Total Liabilities & Shareholders’ Equity 46.222 81.648 117.038 44.555 7.063
Total Common Shares Outstanding 38.9996 38.9276 39.1419 27.8856 23.1846
Short Term Investments 2.872 30.743 0
Long Term Debt 0 2.167 1.436
Other Liabilities, Total 41.877 40.116 9.284 1.935
Cash & Equivalents 34.396 41.625
Current Port. of LT Debt/Capital Leases 0 1.569
Unrealized Gain (Loss) 0 0.005
Dec 2022 Jun 2022 Dec 2021 Sep 2021 Jun 2021
Total Current Assets 38.523 55.729 75.123 94.668 79.842
Cash and Short Term Investments 37.268 51.937 72.368 91.6 76.306
Cash
Prepaid Expenses 1.255 3.792 2.755 3.068 3.536
Total Assets 46.222 63.765 81.648 98.369 82.534
Property/Plant/Equipment, Total - Net 7.352 7.922 3.406 2.333 1.296
Property/Plant/Equipment, Total - Gross 7.903 3.725 2.645 1.591
Accumulated Depreciation, Total -0.551 -0.319 -0.312 -0.295
Other Long Term Assets, Total 0.347 0.114 3.119 1.368 1.396
Total Current Liabilities 7.352 11.109 15.155 18.557 16.571
Accounts Payable 1.081 1.161 1.656 2.128 2.153
Accrued Expenses 4.782 3.513 6.625 10.311 10.444
Notes Payable/Short Term Debt 0 0 0 0
Other Current Liabilities, Total 1.489 6.435 5.305 4.566 1.79
Total Liabilities 52.201 55.657 54.964 60.038 27.226
Total Long Term Debt 0 0 0 0
Long Term Debt 0 0 0
Minority Interest 2.972 3.627 -0.307 0.83 2.487
Other Liabilities, Total 41.877 40.921 40.116 40.651 8.168
Total Equity -5.979 8.108 26.684 38.331 55.308
Common Stock 0.004 0.004 0.004 0.004 0.004
Additional Paid-In Capital 368.857 368.473 369.2 371.209 369.784
Retained Earnings (Accumulated Deficit) -375.276 -360.486 -341.997 -332.484 -314.114
Other Equity, Total 0.436 0.117 -0.523 -0.398 -0.366
Total Liabilities & Shareholders’ Equity 46.222 63.765 81.648 98.369 82.534
Total Common Shares Outstanding 38.9996 38.9554 38.9276 39.1423 39.1419
Cash & Equivalents 34.396 30.74 41.625 63.434 51.306
Current Port. of LT Debt/Capital Leases 0 1.569 1.552 2.184
Short Term Investments 2.872 21.197 30.743 28.166 25
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -36.28 -68.208 -63.821 -40.333 -57.474
Cash From Operating Activities -28.151 -47.242 -43.745 -48.162 -39.955
Cash From Operating Activities 0.232 0.061 0.077 0.077 0.048
Non-Cash Items 1.488 2.497 8.194 2.101 6.253
Changes in Working Capital 7.76 -11.625 2.53 -10.007 11.218
Cash From Investing Activities 18.247 -20.413 -0.052 -0.004 2.867
Capital Expenditures -0.034 -2.844 -0.052 -0.004 -0.207
Other Investing Cash Flow Items, Total 18.281 -17.569 0 0 3.074
Cash From Financing Activities 3.431 0.001 117.835 80.171 13.245
Financing Cash Flow Items 0 -0.082 -0.645 3.33 -0.755
Issuance (Retirement) of Stock, Net 5 0.083 117.81 69.454 14
Foreign Exchange Effects -0.756 -0.258 -0.434 0.039 0.251
Net Change in Cash -7.229 -67.912 73.604 32.044 -23.592
Issuance (Retirement) of Debt, Net -1.569 0 0.67 7.387
Deferred Taxes -1.351 30.033 9.275
Cash Interest Paid 0.017 0.091 0.085
Dec 2022 Jun 2022 Dec 2021 Sep 2021 Jun 2021
Net income/Starting Line -36.28 -68.208 -57.48 -37.337
Cash From Operating Activities -28.151 -47.242 -30.324 -33.152
Cash From Operating Activities 0.232 0.061 0.054 0.037
Deferred Taxes -1.351 30.033 30.026 -0.676
Non-Cash Items 1.488 2.497 4.938 3.792
Cash Interest Paid 0.017 0.091 0.071 0.043
Changes in Working Capital 7.76 -11.625 -7.862 1.032
Cash From Investing Activities 18.247 -20.413 -15.684 -25.022
Capital Expenditures -0.034 -2.844 -0.039 -0.022
Other Investing Cash Flow Items, Total 18.281 -17.569 -15.645 -25
Cash From Financing Activities 3.431 0.001 0.001 0.001
Financing Cash Flow Items 0 -0.082 -0.082 -0.082
Issuance (Retirement) of Stock, Net 5 0.083 0.083 0.083
Issuance (Retirement) of Debt, Net -1.569 0 0 0
Foreign Exchange Effects -0.756 -0.258 -0.096 -0.058
Net Change in Cash -7.229 -67.912 -46.103 -58.231

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

BeyondSpring Inc. Company profile

About Beyondspring Inc

BeyondSpring Inc. is a global biopharmaceutical company that is focused on developing immuno-oncology cancer therapies. The Company’s lead product Plinabulin, which is being studied as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). The Plinabulin product is a marine-derived small-molecule selective immunomodulating microtubule-binding agent (SIMBA) with a range of immune activities. Its Plinabulin has the immune defense protein, GEF-H1, which leads to two effects: a durable anti-cancer benefits due to the maturation of dendritic cells resulting in activation of tumor antigen-specific T-cells to target cancer cells and early-onset action in chemotherapy-induced neutropenia (CIN) prevention after chemotherapy by boosting the number of hematopoietic stem/progenitor cells (HSPCs).

Financial summary

BRIEF: For the nine months ended 30 September 2021,Beyondspring Inc revenues increased from $0K to $1M. Netloss increased 26% to $54.7M. Revenues reflect an increasein demand for the Company's products and services due tofavorable market conditions. Higher net loss reflectsGeneral and administrative - Balancing increase from $10.2Mto $22M (expense), Stock-based Compensation in SGA increaseof 76% to $3.7M (expense).

Industry: Bio Therapeutic Drugs

28 Liberty Street
39th Floor
NEW YORK
NEW YORK 10005
US

Income Statement

  • Annual
  • Quarterly

News

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

Four reasons why Bitcoin is surging to record highs

Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.

10:18, 14 March 2024

China’s National People’s Congress: The markets have again been left wanting more

China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.

08:23, 8 March 2024
Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

13:14, 6 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

People also watch

BTC/USD

70,297.80 Price
-0.580% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

Gold

2,233.43 Price
+1.740% 1D Chg, %
Long position overnight fee -0.0188%
Short position overnight fee 0.0106%
Overnight fee time 21:00 (UTC)
Spread 0.80

US100

18,249.40 Price
-0.200% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 7.0

ETH/USD

3,560.04 Price
-0.080% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading